Tonix Pharmaceuticals Holding Corp. (TNXP): Depreciation & Amortization
$1.90M
Year ended 2025-12-31
$2.10M
Trailing 12 months to 2026-06-30
+13.5%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.90M | -34.5% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $2.90M | -23.7% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $3.80M | +192.3% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $1.30M | n/c | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $50.0K | +85.2% | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | $27.0K | +3.8% | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | $26.0K | -51.9% | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | $54.0K | -15.6% | 2020-03-24, From 2018-01-01 |
| 2017-12-31 | $64.0K | n/a | 2019-03-18, From 2017-01-01 |
| No annual figure between 2015-12-31 and 2017-12-31. | |||
| 2015-12-31 | $96.0K | +166.7% | 2016-03-03, From 2015-01-01 |
| 2014-12-31 | $36.0K | +111.8% | 2016-03-03, From 2014-01-01 |
| 2013-12-31 | $17.0K | n/a | 2016-03-03, From 2013-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $1.90M | -34.5% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $600.0K | +20.0% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $192.0K | -42.5% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $39.0K | +77.3% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $4.51M | +51.3% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $1.71M | -3.4% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $1.91M | +0.7% |
| uniQure N.V. (QURE) | 2025-12-31 | $14.76M | +16.8% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $3.20M | -29.3% |
Compare TNXP, EVMN, CVSI, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗